Fredun Pharmaceuticals

Fredun Pharmaceuticals

965.10
+69.50
(7.76%)
ann
There are new updates from the company1 day ago
Viewcross
right
Market Cap
422.90 Cr
EPS
44.83
PE Ratio
23.08
Dividend Yield
0.07 %
Industry
Healthcare
52 Week High
904.00
52 Week Low
635.00
PB Ratio
3.22
Debt to Equity
0.88
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
neutral
Fredun Pharma has received an adjudication order from the Securities and Exchange Board of India (SEBI). The order does not impose any financial penalty on the company.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,727.50
#1 4,03,712.10
36.18
#1 54,729.00
12.06
#1 10,980
-18.99
65.78
6,790.00
1,79,947.90
82.26
9,360.00
0.89
2,117
23.05
54.56
1,490.90
1,19,863.80
23.41
28,409.50
7.12
5,291
30.28
47.59
3,439.60
1,15,237.30
60.77
11,539.40
11.59
1,911
10.91
65.04
2,651.00
1,11,292.30
55.10
12,207.40
19.57
1,925
-10.91
70.34
1,260.90
1,04,371.50
#1 18.97
33,741.20
12.36
5,725
21.14
42.53
967.65
97,448.70
20.84
22,573.80
13.82
3,977
-0.19
48.60
1,950.70
87,964.10
27.16
22,192.10
#1 19.94
3,024
#1 112.49
50.09
34,275.00
72,874.50
51.57
6,409.15
10.80
1,417
27.83
59.15
1,152.00
66,130.10
19.37
31,378.10
17.55
3,366
-0.50
52.22
Forecast
Actual
Growth Rate
Revenue Growth
26.26 %
Net Income Growth
44.44 %
Cash Flow Change
96.95 %
ROE
14.72 %
ROCE
9.48 %
EBITDA Margin (Avg.)
4.01 %

Quarterly Financial Results

Quarterly Financials
Mar 2025
Revenue
165
Expenses
150
EBITDA
15
Operating Profit %
9 %
Depreciation
2
Interest
8
Profit Before Tax
7
Tax
1
Net Profit
6
EPS in ₹
12.71

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
23
43
56
79
105
141
162
187
257
308
487
Fixed Assets
8
15
16
16
31
31
30
32
39
47
53
Current Assets
13
28
35
52
73
109
130
153
216
257
428
Capital Work in Progress
1
0
4
11
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
1
240
Other Assets
14
29
36
52
74
110
131
155
218
260
0
Total Liabilities
23
43
56
79
105
141
162
187
257
308
487
Current Liabilities
16
32
41
43
53
86
87
74
140
167
327
Non Current Liabilities
4
7
8
14
13
14
32
45
21
19
18
Total Equity
3
4
7
22
39
41
43
68
96
122
141
Reserve & Surplus
1
1
2
19
35
37
39
63
84
115
137
Share Capital
3
3
5
3
4
4
4
4
5
5
5

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
0
1
-1
1
0
2
-2
1
1
-2
Investing Activities
-3
-6
-7
-8
-5
-2
-1
-4
-9
-8
Operating Activities
2
3
4
17
1
-11
0
-2
-14
-0
Financing Activities
1
4
3
-8
4
14
-1
8
25
6

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Nov 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
May 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Apr 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
52.04 %
52.04 %
52.04 %
51.27 %
51.27 %
51.27 %
51.04 %
51.04 %
50.34 %
50.15 %
49.62 %
49.62 %
49.33 %
49.31 %
49.16 %
49.17 %
48.92 %
49.17 %
48.93 %
48.93 %
48.93 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
1.88 %
1.88 %
1.88 %
1.69 %
1.69 %
1.69 %
1.68 %
1.68 %
1.66 %
1.65 %
1.64 %
1.64 %
1.61 %
1.60 %
1.60 %
1.60 %
1.59 %
1.60 %
1.59 %
1.59 %
1.59 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
41.01 %
40.99 %
40.77 %
41.56 %
41.90 %
41.81 %
42.02 %
42.08 %
42.48 %
43.07 %
43.64 %
43.60 %
43.48 %
43.49 %
43.67 %
44.02 %
43.94 %
43.89 %
44.21 %
44.55 %
44.50 %
Others
5.07 %
5.09 %
5.32 %
5.47 %
5.13 %
5.23 %
5.25 %
5.19 %
5.52 %
5.13 %
5.10 %
5.14 %
5.58 %
5.60 %
5.58 %
5.22 %
5.55 %
5.35 %
5.27 %
4.93 %
4.98 %
No of Share Holders
0
1,993
2,301
3,681
3,674
3,573
3,620
3,678
3,901
4,521
4,609
4,625
4,627
4,635
6,315
7,507
6,840
7,511
8,018
8,121
7,976

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.6 1 0.65 0.66 0.7 0.7 0.7 0.7 0.00
Dividend Yield (%) 0.00 0.42 0.24 0.56 0.14 0.08 0.09 0.1 0.1 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 May 2025 724.55 771.00
04 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
04 Feb 2025 700.70 721.85
26 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 Oct 2024 774.70 726.85
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 788.20 755.65
23 Sept 2024 DIVIDEND Dividend
₹ 0.70 /share
23 Sept 2024 981.65 767.60
18 Jan 2024 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
18 Jan 2024 872.05 837.70
22 Sept 2023 DIVIDEND Dividend
₹ 0.70 /share
22 Sept 2023 886.50 875.65
18 Sept 2021 DIVIDEND Dividend
₹ 0.70 /share
16 Sept 2021 415.70 454.45

Announcements

Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Wednesday 30 July 2025.1 day ago
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order5 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20186 days ago
Voluntary Disclosure - SEBI Adjudication Order Dated June 30 2025 (No Penalty Imposed)Jul 03, 2025
Closure of Trading WindowJun 30, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 30, 2025
Announcement under Regulation 30 (LODR)-DemiseJun 20, 2025
Investors Presentation Issued By Fredun Pharmaceuticals Limited Stating Annual Review & Strategic Outlook For Growth In The Pharma IndustryJun 10, 2025
Investor Presentation Of Fredun Pharmaceuticals LimitedJun 10, 2025
Revised Outcome Of The Board Meeting Dated 30.05.2025May 31, 2025
Standalone And Consolidated Audited Financial Results For The Quarter And Financial Year Ended March 31 2025 Along With Statement Of Assets And Liabilities And Cash Flow StatementMay 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 31, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 31, 2025
Standalone And Consolidated Financial Results For The Period Ended On 31St March 2025.May 31, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 31, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Friday 30Th May 2025.May 22, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 17, 2025
Appointment of Company Secretary and Compliance OfficerMay 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 15, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Apr 03, 2025
Closure of Trading WindowMar 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 11, 2025
Intimation With Respect To The Appointment Of Internal Auditor - Disclosure Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing RegulatioFeb 24, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 24, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerFeb 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 04, 2025
Integrated Filing (Financial)Feb 04, 2025
Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2024Feb 04, 2025
Board Meeting Outcome for Outcome Of Board Meeting Dated 04.02.2025Feb 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2025
Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Tuesday 04Th February 2025.Jan 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 09, 2025
Closure of Trading WindowDec 30, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 27, 2024
FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2024Oct 26, 2024
Board Meeting Outcome for OUTCOME OF THE BOARD MEETING HELD ON 26TH OCTOBER, 2024Oct 26, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 19, 2024
Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Saturday, 26Th October, 2024.Oct 15, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 03, 2024
Announcement under Regulation 30 (LODR)-Raising of FundsOct 03, 2024
Announcement under Regulation 30 (LODR)-Issue of SecuritiesOct 03, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On October 03, 2024 Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')Oct 03, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 01, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024

Technical Indicators

RSI(14)
Overbought
81.95
ATR(14)
Volatile
33.44
STOCH(9,6)
Overbought
84.19
STOCH RSI(14)
Overbought
100.00
MACD(12,26)
Bullish
9.57
ADX(14)
Strong Trend
28.52
UO(9)
Bearish
71.05
ROC(12)
Uptrend And Accelerating
18.99
WillR(14)
Overbought
-3.88